Market Closed -
Other stock markets
|
After market 18:30:10 | |||
136 USD | -0.73% | 147.4 | +8.39% |
12:18am | Top law firms in US opioid lawsuits to get hundreds of millions in fees | RE |
06-07 | J&J-backed Rapport Therapeutics shares debut nearly 6% higher | RE |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an enterprise value anticipated at 3.93 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 354B | - | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
-0.78% | 219B | A+ | ||
+11.88% | 216B | B- | ||
+5.90% | 164B | C+ | ||
-0.73% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson